Mechanism of Action of Anti-Inflammatory Drugs

Referenser

• Murphy R C., Hammarström S, Samuelsson Leukotriene B. C. a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA 1979; 76: 4275–9
   PubMed Web of Science ®Google Scholar
• Solomon L M., Juhlin L, Kirchenbaum M B. Prostaglandins on cutaneous vasculature. J Invest Derm 1968; 51: 280–2
   PubMedGoogle Scholar
• Williams T J., Peck M J. Role of prostaglandin-mediated vasodilatation in inflammation. Nature 1977; 270: 530–2
   PubMed Web of Science ®Google Scholar
• Ferreira S H. Prostaglandins, aspirin-like drugs and analgesia. Nature 1972; 240: 200–3
   Web of Science ®Google Scholar
• Saxena P N., Beg M MA, Singhal K C., Ahmad M. Prostaglandin-like activity in the cerebrospinal fluid of febrile patients. Indian J Med Res 1979; 79: 495–8
   Google Scholar
• Higgs E A., Moneada S, Vane J R. Inflammatory effects of prostacyclin (PGI2) and 6-oxo-PGF1 in the rat paw. Prostaglandins 1978; 16: 153–62
   Google Scholar
• Wallner B P., Mattaliano R J., Hession C, Cate R L., Tizard R, Sinclair L K., et al. Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potent anti-inflammatory activity. Nature 1986; 320: 77–81
   PubMed Web of Science ®Google Scholar
• Flower R J., Rothwell N J. Lipocortin-1: cellular mechanisms and clinical relevance. Trends Pharmacol Sci 1994; 15: 71–6
   PubMed Web of Science ®Google Scholar
• Geisow M J., Walker J H., Boustead C, Taylor W. Localisation and structure of novel calcium-regulated phospholipid-binding proteins. Biochem Soc Trans 1987; 15: 800–2
   Google Scholar
• Cirino G, Flower R J. Human recombinant lipocortin 1 inhibits prostacyclin production by human umbilical artery in vitro. Prostaglandins 1987; 34: 59–62
   Google Scholar
• Cirino G, Peers S H., Flower R J., Browning J L., Pepinsky R B. Human recombinant lipocortin 1 has acute local anti-inflammatory properties in the rat paw edema test. Proc Natl Acad Sci USA 1989; 86: 3428–32
   PubMed Web of Science ®Google Scholar
• Barnes P J., Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993; 14: 436–41
   PubMed Web of Science ®Google Scholar
• Wu C-C, Croxtall J D., Perretti M, Bryant C E., Thiemerman C, Flower R J., et al. Lipocortin 1 mediates the inhibition by dexamethasone of the induction by endotoxin of nitric oxide synthase in the rat. Proc Natl Acad Sci USA 1995; 92: 3473–7
   PubMed Web of Science ®Google Scholar
• Fu J-Y, Masferrer J L., Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265: 16737–40
   PubMed Web of Science ®Google Scholar
• Lee S H., Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992; 267: 25934–8
   PubMed Web of Science ®Google Scholar
• Coyne D W., Nickols M, Bertrand W, Morrison A R. Regulation of mesangial cell cyclooxygenase synthesis by cytokines and glucocorticoids. Am J Physiol 1992; 263: F97–F102
   PubMed Web of Science ®Google Scholar
• Vane J R. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971; 231: 232–5
   Web of Science ®Google Scholar
• Smith J H., Willis A L. Aspirin selectively inhibits prostaglandin production in human platelets. Nature 1971; 231: 235–7
   Web of Science ®Google Scholar
• Ferreira S H., Moneada S, Vane J R. Indomethacin and aspirin abolish prostaglandin release from spleen. Nature 1971; 231: 237–9
   Google Scholar
• Van der Ouderaa F J., Buytenhek M, Nugteren D H., van Dorp D A. Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid. Eur J Biochem 1980; 109: 1–8
   PubMedGoogle Scholar
• Vane J R., Flower R J., Botting R M. History of aspirin and its mechanism of action. Stroke 1990; 21(Suppl IV)12–23
   Google Scholar
• Miller T A. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol 1983; 245: G601–G623
   PubMed Web of Science ®Google Scholar
• Robert A, Hanchar A J., Lancaster C, Nezamis J E. Prostacyclin inhibits enteropooling and diarrhea. Prostacyclin, J R. Vane, S Bergström. Raven Press, New York 1979; 147–58
   Google Scholar
• Higgs G A., Vane J R., Hart F D., Wojtulewski J A. Effects of anti-inflammatory drugs on prostaglandins in rheumatoid arthritis. Prostaglandin synthetase inhibitors, H J. Robinson, J R. Vane. Raven Press, New York 1988; 165–73
   Google Scholar
• Flower R J. Drugs which inhibit prostaglandin biosynthesis. Pharm Rev 1974; 26: 33–67
   PubMed Web of Science ®Google Scholar
• Shen T Y. Prostaglandin synthetase inhibitors. Antiinflammatory Drugs, J R. Vane, S H. Ferreira. Springer-Verlag, Berlin 1979; 305–47
   Google Scholar
• Masferrer J L., Zweifel B S., Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexam-ethasone and endotoxin in mice. J Clin Invest 1990; 86: 1375–9
   PubMed Web of Science ®Google Scholar
• Xie W, Chipman J G., Robertson D L., Erikson R L., Simmons D L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692–6
   PubMed Web of Science ®Google Scholar
• O'Banion M K., Sadowski H B., Winn V, Young D A. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991; 266: 23261–7
   PubMed Web of Science ®Google Scholar
• Kujubu D A., Herschman H R. Dexamethasone inhibits mitogen induction of the TIS 10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 1992; 267: 7991–4
   PubMed Web of Science ®Google Scholar
• Sirois J, Richards J S. Purification and characterisation of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem 1992; 267: 6382–8
   PubMed Web of Science ®Google Scholar
• Hemler M, Lands W EM, Smith W L. Purification of the cyclo-oxygenase that forms prostaglandins. Demonstration of the two forms of iron in the holoenzyme. J Biol Chem 1976; 251: 5575–9
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Ogino N, Yamamoto S, Hayaishi O. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 1976; 251: 2629–36
   PubMed Web of Science ®Google Scholar
• Kulmacz R J., Pendleton R B., Lands W EM. Interaction between peroxidase and cyclooxygenase activities in prostaglandin-endoperoxide synthase. Interpretation of reaction kinetics. J Biol Chem 1994; 269: 5527–36
   PubMedGoogle Scholar
• De Witt D. Prostaglandin endoperoxide synthase: Regulation of enzyme expression. Biochim Biophys Acta 1991; 1083: 121–34
   PubMedGoogle Scholar
• Wu K K., Sanduja R, Tsai A L., Ferhanoglu B, Loose-Mitchell D S. Aspirin inhibits interleukin-1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci USA 1991; 88: 2384–7
   PubMed Web of Science ®Google Scholar
• Picot D, Loll P J., Garavito R M. The X-ray crystal structure of the membrane protein. prostaglandin H2 synthase-1. Nature 1994; 367: 243–9
   PubMed Web of Science ®Google Scholar
• Roth G J., Stanford N, Majerus P W. Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sci USA 1975; 72: 3073–6
   PubMed Web of Science ®Google Scholar
• Ryseck R, Raynoscheck C, Macdonald-Bravo H, Dorfman K, Bravo R. Identification of an immediate early gene, PGHs-6, whose protein product has prostaglandin synthase/cyclooxygenase activity. Cell Growth Differ 1992; 3D: 443–50
   Google Scholar
• O'Banion M K., Winn V D., Young D A. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 1992; 89: 4888–92
   PubMed Web of Science ®Google Scholar
• Meade E A., Smith W L., De Witt D L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268: 6610–4
   PubMed Web of Science ®Google Scholar
• O'Neill G P., Mancini J A., Kargman S, Yergey J, Kwan M Y., Falgueyret J P., et al. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: Inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol 1993; 45: 245–54
   Google Scholar
• Preston S J., Arnold M H., Beller E M., Brooks P M., Buchanan W W. Comparative analgesic and anti-inflammatory properties of sodium salicylate and acetylsalicylic acid (aspirin) in rheumatoid arthritis. Br J Clin Pharmacol 1989; 27: 607–11
   PubMed Web of Science ®Google Scholar
• Higgs G A., Salmon J A., Henderson B, Vane J R. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclo-oxygenase and anti-inflammatory activity. Proc Natl Acad Sci USA 1987; 84: 1417–20
   PubMed Web of Science ®Google Scholar
• Whittle B JR, Higgs G A., Eakins K E., Moncada S, Vane J R. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 1980; 284: 271–3
   PubMed Web of Science ®Google Scholar
• Vargaftig B B. Salicylic acid fails to inhibit generation of thromboxane A2 activity in platelets after in vivo administration to the rat. J Pharm Pharmacol 1978; 30: 101–4
   PubMed Web of Science ®Google Scholar
• Flower R J., Vane J R. Inhibition of prostaglandin synthetase in brain explains the antipyretic activity of paracetamol (4-acetamidophenol). Nature 1972; 240: 410–1
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81–106
   PubMed Web of Science ®Google Scholar
• Funk C D., Funk L B., Kennedy M E., Pong A S., Fitzgerald G A. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression and gene chromosomal assignment. FASEB J 1991; 5: 2304–12
   PubMed Web of Science ®Google Scholar
• Bateman D N. NSAIDs: time to re-evaluate gut toxicity. Lancet 1994; 343: 1051–2
   PubMed Web of Science ®Google Scholar
• Laneuville O, Breuer D K., De Witt D L., Hla T, Funk C D., Smith W L. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994; 271: 927–34
   PubMed Web of Science ®Google Scholar
• Kulmacz R J. Topography of prostaglandin H synthase. Antiinflammatory agents and the protease-sensitive argi-nine 253 region. J Biol Chem 1989; 264: 14136–44
   PubMedGoogle Scholar
• Copeland R A., Williams J M., Giannaras J, Nurnberg S, Covington M, Pinto D, et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA 1994; 91: 11202–6
   PubMed Web of Science ®Google Scholar
• Mitchell J A., Akarasereenont P, Thiemermann C, Flower R J., Vane J R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993; 90: 11693–7
   PubMed Web of Science ®Google Scholar
• Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995; 44: 423–33
   PubMed Web of Science ®Google Scholar
• Engelhardt Meloxicam G. A potent inhibitor of COX-2. 9th International Conference on Prostaglandins and Related Compounds, Florence (Italy), June, 6–101994, P82
   Google Scholar
• Klein T, Nüsing R M., Pfeilschifter J, Ullrich V. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 1994; 48: 1605–10
   PubMed Web of Science ®Google Scholar
• Patrignani P, Panara M R., Greco A, Fusco O, Natoli C, Ia-Cobelli S, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271: 1705–12
   PubMed Web of Science ®Google Scholar
• Battistini B, Botting R, Bakhle Y S. COX-1 and COX-2: Toward the development of more selective non-steroid anti-inflammatory drugs. Drug News Perspect 1994; 8: 501–12
   Google Scholar
• Hayllar J, Bjarnason I. NSAIDs, Cox-2 inhibitors, and the gut. Lancet 1995; 346: 521–2
   PubMed Web of Science ®Google Scholar
• Vane J R. NSAIDs, Cox-2 inhibitors, and the gut. Lancet 1995; 346: 1105–6
   PubMedGoogle Scholar
• Bendele A M., Benslay D N., Horn J T., Spaethe S M., Rutebories K J., Lindstrom T D., et al. Anti-inflammatory activity of BF389, a Di-T-butylphenol, in animal models of arthritis. J Pharmacol Exp Ther 1992; 260: 300–5
   Google Scholar
• Wong S, Lee S J., Frierson M R., Proch J, Miskowski T A., Rigby B S., et al. Antiarthritic profile of BF-389 – a novel anti-inflammatory agent with low ulcerogenic liability. Agents Actions 1992; 37: 90–8
   Google Scholar
• Needleman P. search of a better NSAID. 9th International Conference on Prostaglandins and Related Compounds, Florence (Italy), June, 6–101994
   Google Scholar
• Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013–7
   PubMed Web of Science ®Google Scholar
• Isakson P, Seibert K, Masferrer J, Salvemini D, Lee L, Needleman P. Discovery of a better aspirin. Presented at the 9th International Conference on Prostaglandins and Related Compounds, FlorenceItaly, June, 6–101994
   Google Scholar
• Gans K R., Galbraith W, Roman R J., Haber S B., Kerr J S., Schmidt W K., et al. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 1990; 254: 180–7
   PubMed Web of Science ®Google Scholar
• Chan C C., Boyce S, Brideau C, Ford-Hutchinson A W., Gordon R, Guay D, et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995; 274: 1531–7
   PubMed Web of Science ®Google Scholar
• Boyce S, Chan C C., Gordon R, Li C S., Rodger I W., Webb J K., et al. L-745,337: A selective inhibitor of cyclooxygenase-2 elicits antinociception but not gastric ulceration in rats. Neuropharmacology 1994; 33: 1609–11
   Google Scholar
• Hirschelmann R, Hentschel M, Geissler J, Rickinger O. CGP 28238, a new potent nonsteroidal anti-inflammatory agent: Its relation to arachidonic acid metabolism. Agents Actions 1991; 32: 54–5
   Google Scholar
• Weisenberg-Boettcher I, Schweizer A, Green J R., Mueller K, Maerki F, Pfeilschifter J. The pharmacological profile of CGP 28238, a novel highly potent anti-inflammatory compound. Drugs Exp Clin Res 1989; 15: 501–9
   Google Scholar
• Tagari P, Panneton M, Rasori R. Assessment of NSAID gastroenteropathy in primates. Can J Physiol Pharmacol 1994; 72(Suppl 1)267
   Google Scholar
• Parnham M J. Inflammation 93. Drug News Perspect 1994; 6: 737–42
   Google Scholar
• Futaki N, Takahashi S, Yokoyama M, Arai S, Higuchi S, Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H syn-thase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994; 47: 55–9
   PubMed Web of Science ®Google Scholar
• Futaki N, Arai I, Hamasaka Y, Takahashi S, Higuchi S, Otomo S. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J Pharm Pharmacol 1993; 45: 753–5
   PubMed Web of Science ®Google Scholar